ATLANTA—Androgen deprivation therapy (ADT) prior to salvage cryotherapy does not improve biochemical-free survival (BFS) at five years, according to data presented at the American Urological Association 2012 annual meeting.
Amy E. Schlaifer, MD, of Loma Linda University in Loma Linda, Calif., and collaborators examined data from 567 men treated with cryotherapy for biopsy-proven recurrent prostate cancer following radiotherapy. Of these, 222 received ADT prior to cryotherapy and 345 did not. Using Phoenix criteria, the BFS rate was 41.5% and 41% for the ADT and no ADT groups, respectively, a nonsignificant between-group difference.
Stratification into low-, intermediate-, and high-risk groups also demonstrated no significant difference between the groups.
However, functional outcomes at 12 months showed that the ADT group had decreased urine retention and incontinence compared with the no ADT group.
“We think it’s important to consider the risks and benefits prior to placing somebody on ADT before salvage cryotherapy,” Dr. Schlaifer concluded.